0001877990-22-000001.txt : 20220823 0001877990-22-000001.hdr.sgml : 20220823 20220823162927 ACCESSION NUMBER: 0001877990-22-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220823 DATE AS OF CHANGE: 20220823 EFFECTIVENESS DATE: 20220823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praesidia Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001877990 IRS NUMBER: 870985466 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-409716 FILM NUMBER: 221187854 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVE. CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 6692459489 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVE. CITY: ARLINGTON STATE: MA ZIP: 02476 D/A 1 primary_doc.xml X0708 D/A LIVE 0001877990 Praesidia Biotherapeutics, Inc. 1167 MASSACHUSETTS AVE. ARLINGTON MA MASSACHUSETTS 02476 6692459489 DELAWARE None None Corporation true 2021 Sohang Chatterjee 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Executive Officer Director Pradip Majumder 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Executive Officer Martin Lehr 3675 Market St. #200 Philadelphia PA PENNSYLVANIA 19104 Director Shawn Titcomb 275 Commercial Blvd., Suite 333 Lauderdale by the Sea FL FLORIDA 33308 Director John Ripple 1167 Massachusetts Ave. Arlington MA MASSACHUSETTS 02476 Director Biotechnology Decline to Disclose 06b true 0001877990-21-000002 2021-07-30 true true true Praesidia Biologics Inc. merged with and into Praesidia Biotherapeutics, Inc. prior to the offering. 0 Wilmington Capital Securities, LLC 133839 None None 275 Commercial Blvd. Suite 333 Lauderdale by the Sea FL FLORIDA 33308 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO FL FLORIDA IL ILLINOIS IN INDIANA MD MARYLAND MT MONTANA NJ NEW JERSEY NY NEW YORK PA PENNSYLVANIA TX TEXAS true 10000000 4000000 6000000 Total offering is $10,000,000, consisting of first tranche of $4,000,000 and second tranche of $6,000,000. false 55 700000 true 0 Payment of the sales commissions is contingent upon the sale of the full offering amount. 0 true Proceeds of the offering will be used for general working capital of the issuer, including payment of salaries to officers. false Praesidia Biotherapeutics, Inc. Sohang Chatterjee Sohang Chatterjee Chief Executive Officer 2022-08-23